Structure, function and amyloidogenic propensity of apolipoprotein A-1

被引:111
作者
Obici, Laura
Franceschini, Guido
Calabresi, Laura
Giorgetti, Sofia
Stoppini, Monica
Merlini, Giampaolo
Bellotti, Vittorio
机构
[1] Univ Pavia, Dept Biochem, I-27100 Pavia, Italy
[2] IRCCS Policlin San Matteo, Ctr Studio & Cure Amiloidosi Sistemiche, Biotechnol Lab, Pavia, Italy
[3] Univ Milan, Dipartimento Sci Farmacol, Ctr E Grossi Paoletti, Milan, Italy
来源
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS | 2006年 / 13卷 / 04期
关键词
apolipoprotein A-I; HDL; amyloidosis; misfolding;
D O I
10.1080/13506120600960288
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apolipoprotein A-I, the major structural apolipoprotein of high-density lipoproteins, efficiently protects humans from cholesterol accumulation in tissues; however, it can cause systemic amyloidosis in the presence of peculiar amino acid replacements. The wild-type molecule also has an intrinsic tendency to generate amyloid fibrils that localise within the atherosclerotic plaques. The structure, folding and metabolism of normal apolipoprotein A-I are extremely complex and as yet not completely clarified, but their understanding appears essential for the elucidation of the amyloid transition. We reviewed present knowledge on the structure, function and amyloidogenic propensity of apolipoprotein A-I with the aim of highlighting the possible molecular mechanisms that might contribute to the pathogenesis of this disease. Important clues on apolipoprotein A-I amyloidogenesis may be obtained from classical comparative studies of the properties of the wild-type versus the amyloidogenic counterpart. Additionally, in the case of apoA-I, further insights on the molecular mechanisms underlying its amyloidogenic propensity may derive from comparative studies between amyloidogenic variants and other mutations associated with hypoalphalipoproteinemia without amyloidosis.
引用
收藏
页码:191 / 205
页数:15
相关论文
共 91 条
[1]   RETRACTED: Crystal structure of human apolipoprotein A-I: Insights into its protective effect against cardiovascular diseases (Retracted article. See vol. 115, pg. E6966, 2018) [J].
Ajees, AA ;
Anantharamaiah, GM ;
Mishra, VK ;
Hussain, MM ;
Murthy, HMK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (07) :2126-2131
[2]  
Almeida M. R., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P587, DOI 10.2174/156800705774322076
[3]   Extensive intimal apolipoprotein A1-derived amyloid deposits in a patient with an apolipoprotein A1 mutation [J].
Amarzguioui, M ;
Mucchiano, G ;
Häggqvist, B ;
Westermark, P ;
Kavlie, A ;
Sletten, K ;
Prydz, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 242 (03) :534-539
[4]   Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein A-I [J].
Andreola, A ;
Bellotti, V ;
Giorgetti, S ;
Mangione, P ;
Obici, L ;
Stoppini, M ;
Torres, J ;
Monzani, E ;
Merlini, G ;
Sunde, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (04) :2444-2451
[5]  
[Anonymous], 1978, ADV ENZYMOLOGY RELAT
[6]   Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1 [J].
Asl, LH ;
Liepnieks, JJ ;
Asl, KH ;
Uemichi, T ;
Moulin, G ;
Desjoyaux, E ;
Loire, R ;
Delpech, M ;
Grateau, G ;
Benson, MD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :221-227
[7]  
BARRE DE, 1994, J LIPID RES, V35, P1292
[8]   Familial HDL deficiency characterized by hypercatabolism of mature ApoA-I but not ProApoA-I [J].
Batal, R ;
Tremblay, M ;
Krimbou, L ;
Mamer, O ;
Davignon, J ;
Genest, J ;
Cohn, JS .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (04) :655-664
[9]  
Bellotti V, 2005, AMYLOID PROTEINS: THE BETA SHEET CONFORMATION AND DISEASE, VOLS 1 AND 2, P29, DOI 10.1002/9783527619344.ch2
[10]   Ostertag revisited: The inherited systemic amyloidoses without neuropathy [J].
Benson, MD .
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2005, 12 (02) :75-87